123 related articles for article (PubMed ID: 33243262)
1. Clinical trials and drug cost savings for Italian health service.
D'Ambrosio F; De Feo G; Botti G; Capasso A; Pignata S; Maiolino P; Triassi M; Nardone A; Perrone F; Piezzo M; Grimaldi AM; Palazzo I; De Stasio I; D'Aniello R; Morabito A; Pascarella G
BMC Health Serv Res; 2020 Nov; 20(1):1089. PubMed ID: 33243262
[TBL] [Abstract][Full Text] [Related]
2. Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy.
Grossi F; Genova C; Gaitan ND; Dal Bello MG; Rijavec E; Barletta G; Sini C; Donato C; Beltramini S; Pronzato P; Porcile G; Boccardo F; Walzer S
Lung Cancer; 2013 Aug; 81(2):236-40. PubMed ID: 23648072
[TBL] [Abstract][Full Text] [Related]
3. Drug cost savings in phase III hematological oncology clinical trials in a university hospital.
Herledan C; Ranchon F; Schwiertz V; Baudouin A; Karlin L; Ghesquières H; Salles G; Rioufol C
Hematol Oncol; 2020 Oct; 38(4):576-583. PubMed ID: 32469095
[TBL] [Abstract][Full Text] [Related]
4. The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure.
Gasperoni L; Cafaro A; Ferretti E; Di Iorio V; Nanni O; Masini C
Eur J Hosp Pharm; 2023 Mar; 30(2):96-100. PubMed ID: 35577545
[TBL] [Abstract][Full Text] [Related]
5. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan.
Shen LJ; Chou H; Huang CF; Chou GM; Chan WK; Wu FL
Contemp Clin Trials; 2011 Jul; 32(4):485-91. PubMed ID: 21530679
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
7. Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology.
Pascarella G; Capasso A; Nardone A; Triassi M; Pignata S; Arenare L; Ascierto P; Curvietto M; Maiolino P; D'Aniello R; Montanino A; Laudato F; De Feo G; Botti G; Perrone F; Petrillo A; Cavalcanti E; Lastoria S; Maurea N; Morabito A
PLoS One; 2019; 14(1):e0210330. PubMed ID: 30620767
[TBL] [Abstract][Full Text] [Related]
8. Drug cost avoidance in clinical trials of breast cancer.
Mañes-Sevilla M; Romero-Jiménez R; Herranz-Alonso A; Sánchez-Fresneda M; Gonzalez-Haba E; Collado-Borrel R; Benedi-González J; Sanjurjo-Sáez M
J Oncol Pharm Pract; 2019 Jul; 25(5):1099-1104. PubMed ID: 29792122
[TBL] [Abstract][Full Text] [Related]
9. Cost Savings and Waste Reduction Through Redispensing Unused Oral Anticancer Drugs: The ROAD Study.
Smale EM; van den Bemt BJF; Heerdink ER; Desar IME; Egberts TCG; Bekker CL;
JAMA Oncol; 2024 Jan; 10(1):87-94. PubMed ID: 37971730
[TBL] [Abstract][Full Text] [Related]
10. Drug Cost Avoidance in Prostate Cancer Clinical Trials.
Calvin-Lamas M; Portela-Pereira P; Rabuñal-Alvarez MT; Martinez-Breijo S; Martín-Herranz MI; Gómez-Veiga F
Actas Urol Esp; 2015 Nov; 39(9):553-7. PubMed ID: 26071987
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
12. Italian Public Health Expenditure for Vitamin D is still high: New Outlook to Saving From a Consumption Analysis in the Liguria Region.
Moretti M; Paleari L; Figallo F; Garbarini C; Ponti E; Schena F; Marinelli L
Clin Ther; 2021 Nov; 43(11):1969-1982. PubMed ID: 34756467
[TBL] [Abstract][Full Text] [Related]
13. Expected net benefit of clinical pharmacy in intensive care medicine: a randomized interventional comparative trial with matched before-and-after groups.
Claus BO; Robays H; Decruyenaere J; Annemans L
J Eval Clin Pract; 2014 Dec; 20(6):1172-9. PubMed ID: 25470782
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of drug cost savings related to clinical trials from the perspective of a university hospital.
Perrier Q; Minoves M; Cerana S; Reymond F; Ducki C; Decaens T; Lehmann A; Bedouch P
Eur J Hosp Pharm; 2023 May; ():. PubMed ID: 37248032
[TBL] [Abstract][Full Text] [Related]
15. The costs of childhood epilepsy in Italy: comparative findings from three health care settings.
Guerrini R; Battini R; Ferrari AR; Veggiotti P; Besana D; Gobbi G; Pezzani M; Berta E; Tetto A; Beghi E; Monticelli ML; Tediosi F; Garattini L; Russo S; Rasmini P; Amadi A; Quarti P; Fabrizzi R;
Epilepsia; 2001 May; 42(5):641-6. PubMed ID: 11380572
[TBL] [Abstract][Full Text] [Related]
16. The pharmacoeconomic impact of amlodipine use on coronary artery disease.
De Portu S; Menditto E; Scalone L; Bustacchini S; Cricelli C; Mantovani LG
Pharmacol Res; 2006 Aug; 54(2):158-63. PubMed ID: 16814560
[TBL] [Abstract][Full Text] [Related]
17. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
18. Current national initiatives about drug policies and cost control in Europe: the Italy example.
Rocchi F; Addis A; Martini N;
J Ambul Care Manage; 2004; 27(2):127-31. PubMed ID: 15069990
[TBL] [Abstract][Full Text] [Related]
19. Using 2nd generation basal insulins in type 2 diabetes: Costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study.
Napoli R; Fanelli F; Gazzi L; Larosa M; Bitonti R; Furneri G
Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):1937-1944. PubMed ID: 32912786
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
